ASPIRE EMRISTA | Areas of Interest

The Emerging Markets Thrombosis Investigator-Initiated Research Program (EMRISTA) is established to fund innovative medical research from researchers across Pfizer’s Emerging Markets, including Africa, Asia, Latin America and the Middle East. The key objective of the program is to encourage the generation of new data to improve patient care for those requiring oral anticoagulation treatment in relevant disease areas, areas of unmet medical need, or areas of special interest.

Areas of research eligible for the program:

  • Advance the understanding of the practical use of non-vitamin K oral anticoagulants (NOACs), in non-valvular atrial fibrillation (NVAF), treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
  • Advance the understanding of use of NOACs in real-world clinical practice settings in the approved indications.
  • Advance the understanding of patient adherence to therapy, the appropriate use of NOACs and their impact on quality of life, and health-related outcomes.
  • Advance the understanding of bleeding management related to the use of NOACs
  • Other potential areas of interest and/or unmet need involving anticoagulation.

Areas of Research NOT eligible for funding:

  • Studies utilizing a competitor product only
  • Patient populations where the risk of NOACs use is greater than the benefit
  • A use that is contraindicated in the apixaban prescribing information or outside of product label
  • Pregnant and lactating women
  • Any head-to-head clinical trial comparison of apixaban versus another novel oral anticoagulant [NOAC])
  • Repeat/duplication of research, (e.g. ablation, reversal or “acute” cardioversion)
  • Repeat of any Phase 3 trials
  • Any pharmacokinetic/pharmacodynamic properties described in the USPI e.g. crushed tablets, hemodialysis
  • Reducing the recurrence of acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)
  • Post-coronary artery bypass graft (CABG) patients, patients with prosthetic (mechanical and bioprosthetic) heart valves or devices
  • Patients with any atherothrombotic or hemorrhagic stroke, or any stroke within 7 days
  • Venous thromboembolism prophylaxis (VTEp) in patients with stroke and hemiparesis
  • Evaluation of the safety of apixaban in patients with end-stage renal disease on hemodialysis
  • Efficacy of apixaban in secondary prevention of TIA/CVA.